TP53 Status as Determinant of ESR2 Effects in Breast Cancer TP53 Status as Determinant of ESR2 Effects in Breast Cancer

Therapeutic modification of the mutant TP53-ESR2 interaction with agents such as tamoxifen may offer promise for triple negative breast cancer.Journal of the National Cancer Institute

Source: Medscape Today Headlines - January 3, 2020 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news